# Biocon Q1 Income Rises 9% as Biopharma Revenue Grows 17%

2026-08-07T00:50:57+00:00 | Business & Economy | Indian Opinion Desk

Corroboration: 1 independent outlet

Biocon’s total income rose 9 per cent year on year to Rs 4,391 crore in the first quarter of FY27, Business Today TV reported. EBITDA stood at Rs 902 crore and net profit at Rs 141 crore. Biopharma revenue increased 17 per cent, supported by recent biosimilar and generic launches in key markets. Deccan Herald reported that profit rose more than fourfold, without specifying the comparison or profit figure. Chief executive Shreehas Tambe said sustained profitability would depend on product mix and spreading fixed costs across Biocon’s global operations. The company also received regulatory approval for its insulin fill-finish facility in Malaysia and expects growth to accelerate through the year.

## Coverage

- businesstoday.in <https://www.businesstoday.in/bt-tv/whats-hot/video/biocon-posts-9-rise-in-q1-total-income-biopharma-revenue-up-17-547665-2026-08-06?utm_source=rssfeed>
- deccanherald.com <https://www.deccanherald.com/business/companies/biocon-reports-over-4-fold-rise-in-profit-on-biopharma-growth-4102226>

Tags: Biocon, biopharma, biosimilars, pharmaceuticals, Q1 results
Canonical: https://indianopinion.org/biocon-q1-income-rises-9-to-rs-4391-crore/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/biocon-q1-income-rises-9-to-rs-4391-crore/#story-in-brief

Review state: restored archive article, accurate at time of publication, not offered to search indexes.